$KTRANot financial advice. NASDAQ:KTRA weekly chart looks like wants to break this downtrend line.. Inside candle for those familiar with the STRAT Like and subscribe for more ideas.by alex6666663
KTRA oversold! Price target and stop lossKintara Therapeutics, Inc. (KTRA) oversold on the daily! Based on support and resistance we have: Price target: 2.60usd Stop loss: 0.58usdLongby TopgOptions8
$KTRA price holding on strong support$KTRA price is holding on strong support. Waiting to see for a bounceLongby CoinVigilante110
KTRA Bullish SetupShort term MAs are crossing the longer term MAs and the MACD is rising. I like yesterday's candle retesting the 0 fib level m testing the .38 level and closing above the .23 fib level. Looking for a break of 1.76 to enter for a swing trade. target: 1.92 in the short term. Longby Master_of_Fine_Charts0
KTRA 2x Phase two drugs data due soon.100m shelf popped out of the blue, now in effect. Phase two data is due and looks to be positive. Cap is under 60m. Seems very undervalued here. The shelf is strange because the CEO has stated that they had enough cash to get through Q4/21, so why the offering now? by mooonshine1990
Technical + Potential Catalyst. Low risk high rewardBroke out of a trend line and retested 1.30, looks to be heading towards 1.80 based on the sideways pattern. If it breaks out of sideways pattern there may be more upside. Stop loss can be somewhere below the sideways pattern. Kintara will be presenting in H.C. Wainwright Bioconnect 2021 Virtual Conference on January 11 – January 14, 2021. I am expecting them to receive positive exposure through presentation of their various positive topline data from phase 2 trials, providing more specifics and announcement of first patient enrolment into their phase 3 Glioblastoma Multiforme (GBM) trial. - VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory GBM and is currently being studied in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM. - Glioblastoma Multiforme is the most common and lethal form of brain cancer. - VAL-083 has been assessed in 42 Phase 1 and Phase 2 clinical trials sponsored by the U.S. National Cancer Institute ("NCI") as a treatment against various cancers. - VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia ("CML") and lung cancer. Longby trilliondollarUpdated 337
Kintara Therapeutics, Inc. On Breakout Alert Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.Longby DEXWireNews2